Clinical trials: Patient With Schizophrenia Spectrum Disorder
Schizophrenia, Schizoaffective Disorder
Effectiveness of Ziprasidone for Patients With Schizophrenia
This study is designed with the aim to evaluate the clinical effect of the overlapped switching to ziprasidone as well as the efficacy and safe metabolic profile of ziprasidone.
- Trial name
- NCT01198353
- Testing
- Ziprasidone
- Where
- 6 sites in South Korea
- Volunteers
- 67 people
- Sponsor
- Soonchunhyang University Hospital
Psychomotor Retardation, Psychomotor Slowing
Transcranial Magnetic Stimulation (TMS) for Motor Symptoms in Psychiatric Disorders
Psychomotor slowing may occur in major psychiatric disorders, such as major depressive disorders or schizophrenia spectrum disorders. It refers to slowing of fine motor skills, motor planning and gross motor behavior.
- Conditions
- Psychomotor Retardation, Psychomotor Slowing, Schizophrenia and Related Disorders, Major Depressive Disorder
- Trial name
- NCT03275766
- Testing
- DLPFC facilitatory, SMA inhibitory, SMA facilitatory
- Where
- Switzerland
- Volunteers
- 45 people
- Sponsor
- University of Bern
Cancer, Severe Major Depression
Bridge: Proactive Psychiatry Consultation and Case Management for Patients With Cancer
The purpose of this research is to understand if it is helpful for patients with mental illness to be connected to a psychiatrist and case manager at the time of cancer diagnosis.
- Conditions
- Cancer, Severe Major Depression, Schizophrenia, Bipolar Disorder
- Trial name
- NCT03360695
- Testing
- Proactive Psychiatry Consultation (PPC), Enhanced Usual Care (EUC)
- Where
- United States
- Volunteers
- 185 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Schizo Affective Disorder
Telmisartan Pilot Study on Treatment Resistant Schizophrenia
This study is a 4-week pilot study for subjects with Schizophrenia or Schizoaffective Disorder who have not experienced a significant relief of symptoms from current anti-psychotic medication.
- Conditions
- Schizophrenia, Schizo Affective Disorder, Treatment-resistant Schizophrenia
- Trial name
- NCT03868839
- Testing
- Telmisartan Pill
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Xiaoduo Fan
Schizophrenia Disorder, Frontotemporal Dementia, Behavioral Variant
Understanding Mechanisms of Synaptic Degeneration Underlying Clinical Symptoms in Patients With MDs and NDs.
Clinical Study A. Retrospective Neuropathological Study of Synapse dysfunction. This is a cross-sectional study of patients retrospectively collected from existing postmortem collections and from existing collections of…
- Conditions
- Schizophrenia Disorder, Frontotemporal Dementia, Behavioral Variant, Major Depressive Disorder (MDD), Bipolar Disorder (BD)
- Trial name
- NCT07234851
- Where
- Spain
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Affective Psychosis, Bipolar, Bipolar Disorder
A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety over a 6-week period of paliperidone ER compared with placebo in treating subjects with Bipolar I Disorder who are experiencing a manic or mixed episode while…
- Conditions
- Affective Psychosis, Bipolar, Bipolar Disorder, Mania
- Trial name
- NCT00309686
- Testing
- Paliperidone ER
- Volunteers
- 300 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia Patients, Auditory Hallucination
Effect of Cognitive Behavioral Therapy on Auditory Hallucinations and NLR in Schizophrenia Patients
This study aims to evaluate the effectiveness of Cognitive Behavioral Therapy (CBT) as an adjunctive treatment to pharmacotherapy in reducing auditory hallucinations and inflammation, as measured by the neutrophil-to-lymphocyte…
- Trial name
- CBT-SCZ-NLR (NCT07524868)
- Testing
- Cognitive Behavioral Therapy (CBT), risperidone
- Where
- Indonesia
- Volunteers
- 50 people
- Sponsor
- Hasanuddin University
Schizophrenia
A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.
The purpose of this study is to determine if adding extended-release galantamine hydrobromide, compared with adding placebo, to current atypical antipsychotic therapy is well tolerated and effective in improving cognitive…
- Trial name
- NCT00077727
- Testing
- Extended-release galantamine hydrobromide
- Volunteers
- 107 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizoaffective Disorder
The Antiatherogenic Properties of HDL in Psychiatric Patients With and Without Antipsychotic Therapy
Background: Among individuals with schizophrenia, there is an increased prevalence of obesity, dyslipidemia ,diabetes mellitus and related conditions such as cardiovascular disease.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT01215383
- Where
- Israel
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Ziv Hospital
Schizophrenia
Cognitive Functioning Related to Job Tenure Among Patients With Schizophrenia
The aim of this research is to explore which cognitive function would affect the job tenure among people with schizophrenia. The investigators plan to recruit 60 people diagnosed with schizophrenia and divide into two groups…
- Trial name
- NCT00838123
- Volunteers
- 60 people
- Sponsor
- Far Eastern Memorial Hospital
Childhood Onset Psychotic Disorders, Schizophrenia
Transcranial Direct Current Brain Stimulation to Treat Patients With Childhood-Onset Schizophrenia
This study will test whether transcranial direct current stimulation (TDCS) can be used safely in children with schizophrenia and if it can improve memory and attention span or auditory hallucinations in these children, at least…
- Conditions
- Childhood Onset Psychotic Disorders, Schizophrenia, Psychosis, Mental Disorders
- Trial name
- NCT00757497
- Testing
- Electrical Polarization
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Mental Health (NIMH)
Severe Mental Disorder, Metabolic Complication
Effectiveness of a Pragmatic, Metabolic Care Clinic for Patients With Severe Mental Illness - The Meta Care Clinic
This study will examine the effectiveness of a Pragmatic, Metabolic Care Clinic for Patients With Severe Mental Illness
- Conditions
- Severe Mental Disorder, Metabolic Complication, Side-Effect;Medication, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- NCT06624462
- Testing
- Treatment in the Meta Care Clinic, Standard care with general practitioner and/or outpatient clinics
- Where
- Denmark
- Volunteers
- 84 people
- Sponsor
- Bjorn H. Ebdrup
Schizophrenia
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
This is a 12-week, multi-center, open-label extension study designed to evaluate the longer-term safety, tolerability and effectiveness of lurasidone for the treatment of subjects with schizophrenia.
- Trial name
- NCT01566162
- Testing
- Lurasidone
- Where
- 63 sites in United States, France and 5 more
- Volunteers
- 191 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia
Pharmacokinetics and Tolerability Study of Risperidone ISM® in Schizophrenia
To characterize the pharmacokinetics (PK) of the injectable intramuscular (IM) long-acting formulation (in situ microparticle, ISM) of risperidone over four IM injections in the gluteal and deltoid muscle at 28-day intervals and…
- Trial name
- PRISMA-2 (NCT02086786)
- Testing
- Risperidone ISM
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Schizophrenia
Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia
This study is to assess the pharmacodynamics, pharmacokinetics, safety and tolerability of multiple ascending doses of AZD0328 in patients with schizophrenia
- Trial name
- NCT00669903
- Testing
- AZD0328
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Schizophrenia
Efficacy and Safety Study of Clozapine Augmented by Atomoxetine Versus Clozapine Augmented by Placebo in Patients With Chronic Resistant Schizophrenia
This is a randomized, placebo-controlled study to assess the efficacy and safety of ATX augmentation of CLZ as a treatment for the cognitive symptoms of schizophrenia.
- Trial name
- NCT00216281
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Indiana University
Schizophrenia
Safety and Efficacy of MP-214 in Patients With Schizophrenia
The objective of this study is to evaluate the efficacy, safety, and tolerability of MP-214 relative to placebo in patients with acute exacerbation of schizophrenia.
- Trial name
- NCT01625000
- Testing
- MP-214 3mg, MP-214 6mg, MP-214 9mg
- Where
- 3 sites in Japan, South Korea and 1 more
- Volunteers
- 512 people
- Sponsor
- Tanabe Pharma Corporation
Metabolic Syndrome
Adjunctive Low-dose Metformin in Patients With Schizophrenia and Metabolic Abnormalities
Metformin has been used for alleviating metabolic abnormalities in patients with schizophrenia. Until now, the lowest dose of metformin to treat metabolic abnormalities in clozapine-treated patients is 1000 mg/d.
- Trial name
- NCT02751307
- Testing
- metformin 500 mg, clozapine 100 mg
- Volunteers
- 55 people
- Sponsor
- Taipei Medical University WanFang Hospital
Schizophrenia
A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in Patients With Schizophrenia
The purpose of this study is to assess the pharmacokinetics, safety, and tolerability of a paliperidone palmitate 3-month formulation in patients with schizophrenia.
- Trial name
- NCT01559272
- Testing
- Paliperidone IR (Period 1), Paliperidone palmitate F015 (Panel A: treatment group 1), Paliperidone palmitate F015 (Panel A: treatment group 2)
- Where
- 36 sites in United States, Belgium and 9 more
- Volunteers
- 328 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia, Therapeutics
Berberine Effects on Clinical Symptoms and Metabolic Disturbance in Patients With Schizophrenia
The study was a 8-week, randomized, double-blind, placebo-controlled trial. Berberine (300 mg，three times a day), as an adjuvant therapy has been used on the basis of the Second-generation antipsychotics（SGAs） monotherapy.
- Trial name
- NCT03548155
- Testing
- Berberine, atypical antipsychotic
- Volunteers
- 65 people
- Sponsor
- Tianjin Anding Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.